Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market
Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...
eLife2d
Noncaloric monosaccharides induce excessive sprouting angiogenesis in zebrafish via foxo1a-marcksl1a signal
Live imaging and single-cell sequencing analyses on zebrafish models revealed that noncaloric monosaccharides and glucose similarly induce excessive blood vessel formation due to endothelial cells' ...
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that we have completed enrollment ...
thearabianpost4d
Thymosin Beta-4 Peptide: Unveiling Its Potential in Regenerative Studies
Thymosin Beta-4 (Tβ4) is an endogenously occurring peptide that has drawn significant attention from the scientific community due to its wide-ranging biological properties. Composed of 43 amino acids, ...